@article{edd417cb51f4412582bb07fd01573aab,
title = "Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept",
keywords = "non-small cell lung cancer, pembrolizumab, atezolizumab, nivolumab, immunotherapy, checkpoint inhibition, CELL LUNG-CANCER, QUALITY-OF-LIFE, IMMUNE-CHECKPOINT INHIBITORS, OPEN-LABEL, 1ST-LINE TREATMENT, NEOADJUVANT CHEMOTHERAPY, ANTI-PD-1 ANTIBODY, COST-EFFECTIVENESS, NIVOLUMAB, PEMBROLIZUMAB",
author = "Thierry Berghmans and Valerie Durieux and Hendriks, {Lizza E. L.} and Anne-Marie Dingemans",
year = "2020",
month = mar,
day = "24",
doi = "10.3389/fmed.2020.00090",
language = "English",
volume = "7",
journal = "Frontiers in medicine",
issn = "2296-858X",
publisher = "Frontiers Media S.A.",
}